Capstan Medical, which is developing heart valve implants with a robotic delivery platform, said Wednesday it has secured $110 million in new funding to advance its work leading to upcoming pivotal ...
"Marshall’s rich experience strengthens our board as we move into our next phase of growth," CEO Maggie Nixon said.
A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the body is being acquired by pharmaceutical giant AbbVie for $2.1 billion in ...
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is ...
AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn. The agreement will give AbbVie access to Capstan’s lead CAR-T therapy ...
AbbVie announced this morning it would buy clinical-stage biotech company Capstan Therapeutics for up to $2.1 billion in cash, picking up the company's in vivo CAR-T therapy candidate. San Diego-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback